araag2/HINT huggingface dataset:
Clinical trial NCT00687817 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bavituximab plus paclitaxel and carboplatin
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Key Inclusion Criteria:

          -  Adults over age 18 years of age with a life expectancy of at least 3 months

          -  Histologically or cytologically confirmed non-small cell lung cancer at stage IIIB
             (with pleural effusion), stage IV, or recurrence

          -  Measurable disease on cross sectional imaging at least 2 cm in longest diameter (1 cm
             if measured by spiral CT)

          -  Adequate hematologic (ANC ≥ 1500 cells/µL; Hemoglobin ≥9 g/dL; platelets ≥100,000/µL
             and ≤500,000/µL ), renal (serum creatinine ≤ 1.5 mg/dL or calculated creatinine
             clearance ≥ 60 mL/min), and hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN,
             AST ≤ 3 x ULN)

          -  D-dimer ≤ 2 x ULN

        Key Exclusion Criteria:

          -  Small cell or mixed histology

          -  Known history of bleeding diathesis or coagulopathy

          -  Any current evidence of clinically significant bleeding defined as gross hematuria,
             hemoptysis, or GI bleeding

          -  Any history of thromboembolic events (e.g., deep vein thrombosis or pulmonary
             thromboembolism)

          -  Prior chemotherapy, immunotherapy or radiotherapy to an area of measurable disease
             unless disease had recurred after radiotherapy

          -  Radiotherapy within 2 weeks preceding Study Day 1

          -  Symptomatic or clinically active CNS disease or metastatic lesions

          -  Major surgery within 4 weeks of Study Day 1

          -  Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)

          -  Any history of angina pectoris, coronary artery disease or cerebrovascular accident,
             or transient ischemic attack

          -  A history of any condition requiring anti-platelet therapy with the exception of
             general cardiovascular prophylaxis with aspirin. Anti-platelet agents are prohibited
             during the study.

          -  Requirement for chronic daily treatment with NSAIDs, anti-platelet drugs, or steroids
Clinical trial NCT01453569 (phase 2, status: completed)
Conditions: alzheimer disease, cognitive impairment
ICD codes: G30.8, G30.9, G30.0, G30.1, G31.84
Drugs: sodium oligo-mannurarate 600mg, sodium oligo-mannurarate 900mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  At least primarily educated.

          -  Accord with Probable Alzheimer disease of National Institute of Neurological and
             Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders
             Association(NINCDS-ADRDA)'s Criteria.

          -  10 points ≤ Minimum Mean-Square Error(MMSE) ≤ 24 points.

          -  Hachinski ischemia scale <4 points.

          -  Hamilton depression scale ≤10 points.

          -  Should have stable accompanying person, or at least contact 2 hours per day, 4 days
             per week with accompanying person. The accompanying person should help the patient
             throughout the trial.

          -  Signed the information consent form.

        Exclusion Criteria:

          -  Have been in other clinical trials within 30 days before this trial' start.

          -  women during pregnancy or lactation.

          -  Dementia caused by other diseases.

          -  previous nervous system diseases.

          -  Abnormal laboratory results.

          -  Uncontrolled hypertension.

          -  Unstable or serious diseases of heart, lung, liver, kidney and blood.

          -  Visual or auditory handicap.

          -  Significant focal lesions revealed by electronic computer X-ray tomography(CT) or
             magnetic resonance imaging(MRI) in one year before enrollment.

          -  Alcohol abuse or drug abuse.

          -  psychotic, including patients with serious depression.

          -  Patients being in drug therapy of Alzheimer disease which cannot be stopped.

          -  In treatment of heparin, Polysaccharide sulfate, mannose ester 3 weeks before the
             recruitment.

          -  Investigator consider the patient cannot finish this trial for any reason.

          -  Relatives or employees of the investigators, staff of the investigate centers,
             contract research organization and sponsor.
Clinical trial NCT00438607 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: biib014, placebo
SMILES: CC1=CC(CN2N=NC3=C(N=C(N)N=C23)C2=CC=CO2)=CC=C1N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must carry a diagnosis of idiopathic PD according to UK Parkinson's Disease Society
             Brain Bank Clinical Diagnostic Criteria, and be Hoehn & Yahr Stage II to IV
             (inclusive) when OFF.

          -  Must be on a stable dose of L-3,4-dihydroxyphenylalanine (L-DOPA)/carbidopa or
             L-DOPA/benserazide for at least 4 weeks prior to enrollment.

          -  Except for L-DOPA and certain allowed dopamine agonists, must not be receiving any
             other PD medications. (Current treatment with certain dopamine agonists is allowed but
             subjects must have been on a stable dose for at least 4 weeks prior to enrollment).

          -  Some subjects must demonstrate a definite end of L-DOPA dose wearing off (at least 2
             hours OFF time per waking day) and must be able to keep accurate patient diaries of PD
             activity.

        Major Exclusion Criteria:

          -  A Mini Mental State Examination (MMSE) score <26.

          -  History or clinical features consistent with an atypical parkinsonian syndrome.

          -  Any significant non-Parkinson's central nervous system disorder.

          -  Any significant AXIS I psychiatric disease from the Diagnostic and Statistical Manual
             of Mental Disorders (DSM).

          -  Any previous surgical intervention for Parkinson's Disease.

          -  History of certain malignancies.

          -  History of severe allergic anaphylactic reactions to any drug.

          -  Clinically significant baseline electrocardiogram (ECG).

          -  Orthostatic hypotension.

          -  HbA1c >7.0%
Clinical trial NCT00601484 (phase 2, status: completed)
Conditions: cystitis, interstitial
ICD codes: N30.10, N30.11
Drugs: pf-04383119, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adults at least 18 years of age;

          -  Moderate to severe interstitial cystitis, with a mean pain intensity score above a
             pre-defined level.

        Exclusion Criteria:

          -  Less than 6 months since onset of interstitial cystitis symptoms;

          -  History of recurrent urinary tract infections, or genitourinary cancer;

          -  History of hepatitis B, C or human immunodeficiency virus (HIV);

          -  Use of certain drugs given into the bladder up to 1 month prior to study entry.
Clinical trial NCT00459953 (phase 2/phase 3, status: completed)
Conditions: nicotine dependence
ICD codes: F17.200, F17.210, F17.208, F17.209, F17.218, F17.219, F17.228
Drugs: extended treatment
SMILES: CN1CCC[C@H]1C1=CN=CC=C1
Eligibility criteria:

        Inclusion Criteria:

        Age 14-18 at the beginning of the study

        Smoking at least 10 cigarettes per day

        At least one quit attempt in previous 6mos

        Exclusion Criteria:

        Current DSM-IV disorder (depression, panic disorder, social anxiety disorder and
        agoraphobia)

        Current self report of daily or heavy use (more than three times per week) of any drugs
        (marijuana, alcohol, cocaine, opiates, stimulants, etc.)

        Positive urine pregnancy test

        Currently on bupropion (Wellbutrin, Wellbutrin SR, Zyban) or other antidepressants, MAOI's,
        antipsychotics, benzodiazepines

        Currently on NRT

        Currently receiving formal treatment for substance abuse problem, depression or anxiety
Clinical trial NCT00661609 (phase 2, status: completed)
Conditions: bladder cancer, transitional cell bladder cancer, urethra cancer, ureter cancer, renal pelvis cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: azd4877
SMILES: CC(C)C(N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=C(C(C)=NS2)C(=O)N1CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra).

          -  Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by
             curative surgery and/or curative radiotherapy

          -  Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable
             and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting.

          -  Ambulatory and capable of all selfcare more than 50% of waking hours

        Exclusion Criteria:

          -  Prior treatment with investigational or standard anti-cancer agents, including
             radiotherapy, within 4 weeks prior to first dose of study medication; 6 weeks if prior
             systemic mitomycin, nitrosourea, or suramin.

          -  Inadequate bone marrow reserve

          -  Inadequate liver function in the presence of liver metastases

          -  Impaired renal function
Clinical trial NCT01694537 (phase 2, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: dlbs1033, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male

          -  18-55 years old

          -  body mass index between 18-25 kg/square metres

          -  normal physical examination

          -  Patient still have the ability to undergo examinations and give written informed
             consent

          -  Plasmin-antiplasmin complex (PAP complex) level between 0-514 ng/ml

          -  Platelet aggregation (ADP 10 uM) > 49%

        Exclusion Criteria:

          -  Patient with cardiovascular disease, hypertension, diabetes mellitus, and dyslipidemia

          -  Creatinin serum more than 1,5 x upper limit normal

          -  SGOT and SGPT more than 3 x upper limit normal

          -  Blood pressure ≥ 140/90 mmHg

          -  Fasting blood glucose > 126 mg/dL

          -  Alcohol patients

          -  Took any medications (including traditional medicine, supplement and vitamin) in 1
             week before the study)

          -  Patient has bleeding history which unclear etiology

          -  Hemoglobin < 10 g/dL

          -  Thrombocyte count < 100.000/uL

          -  Heavy smoker (Bringman Index > 600)
Clinical trial NCT01004510 (phase 2, status: terminated)
Conditions: malignant pleural effusion, non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: zoledronic acid
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Reason stopped: 
    failure to accrue projected number of patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented non-small cell lung cancer, Stages 3B, 4 or recurrent

          -  Pleural effusion cytologically proven to be malignant

          -  0 or 1 prior chemotherapy regimens for non-small cell lung cancer (adjuvant
             chemotherapy post resection, or concurrent chemo-radiation therapy counts as one
             regimen regardless of number of agents used.)

          -  Planning to start chemotherapy for non-small cell lung cancer (treatment regimen at
             discretion of treating physician but must include one or more of the following
             agents:cisplatin,carboplatin,docetaxel,paclitaxel, pemetrexed,gemcitabine,vinorelbine)
             Patients may receive anti-angiogenesis agents (bevacizumab) in addition to
             chemotherapy, but patients treated solely with tyrosine kinase inhibitors or
             growth-factor receptor blockers are not eligible.

          -  Prior radiation therapy is permitted.

          -  Performance status 0,1,2

          -  Serum creatinine less than 2.0 or estimated creatinine clearance over 30cc/min by
             Calcroft/Gault equation

          -  Estimated life expectancy over 3 months

          -  Signed informed consent

          -  Age greater than 18 years

          -  Patients who have clinical indication for Zometa treatment such as lytic bone
             metastases or hypercalcemia can be included

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Patient with concurrent medical or psychiatric illness which would, in the opinion of
             the investigator, prevent compliance with the study

          -  Patients who undergo any procedure other than thoracentesis for drainage of
             effusion.Patients may have had more than one thoracentesis prior to study. Patients
             who have large bore chest tube placement, permanent transthoracic catheter (Pleurex),
             medical pleurodesis or thoracoscopy are excluded.

          -  Current active dental problems including infection of the teeth or jawbone (maxilla or
             mandibular);dental or fixture trauma, or a current or prior diagnosis of osteonecrosis
             of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental
             procedures.

          -  Recent (within 6 weeks)or planned dental or jaw surgery (e.g.extraction, implants).
Clinical trial NCT00501592 (phase 2, status: completed)
Conditions: diabetes mellitus, type ii, fatty liver
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, K70.0, K76.0
Drugs: int-747, placebo
SMILES: [H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)[C@]([H])(CC)[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes, defined by the American Diabetes Association (ADA), as one of the
             following criteria:

          -  Symptoms of diabetes plus casual plasma glucose concentration >200 mg/dL (11.1 mmol/L)
             or

          -  Fasting plasma glucose >126 mg/dL (7.0 mmol/L) or

          -  2-hour post-load glucose >200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance
             test (GTT).

          -  Presumed NAFLD, defined by one of the following criteria:

          -  Alanine aminotransferase (ALT) ≥47 U/L for females and ≥56 U/L for males

          -  Aspartate aminotransferase (AST) ≥47 U/L for females and ≥60 U/L for males

          -  Enlarged liver (demonstrated by ultrasound or other imaging technique)

          -  Diagnostic histological findings shown on prior biopsy (in the last 5 years).

        Exclusion Criteria:

          -  Bilirubin >2 × ULN

          -  ALT >155 U/L for females and >185 U/L for males.

          -  AST >155 U/L for females and >200 U/L for males.

          -  Patients taking any antidiabetic medications, with the exception of metformin and
             sulfonylureas. If the HbA1c is <11%, patients may be enrolled who have been withdrawn
             from all other diabetic medications as specified in the protocol, at the discretion of
             the Principal Investigator.
Clinical trial NCT01098734 (phase 2, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: wbi-1001
SMILES: CC(C)C1=C(O)C=C(\C=C\C2=CC=CC=C2)C=C1O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of chronic atopic dermatitis (Hanifin's criteria) for greater than
             6 months with a minimum of 5% and a maximum of 20% BSA.

          -  IGA scores of 2-4 at Day 0.

          -  WOCBP must have a negative serum beta-hCG pregnancy test before randomization, and
             they and their male partners must take pregnancy precautions for the duration of the
             study, as also must male patients.

          -  Willing to comply with Protocol and attend all visits.

          -  Provide written informed consent prior to entering study procedures.

          -  Patient has no latent or active tuberculosis infection according to medical history or
             current examination and tests.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Spontaneously improving or rapidly deteriorating atopic dermatitis.

          -  Presence of atopic dermatitis on only hands and/or feet.

          -  Any skin disease other than atopic dermatitis that might interfere with clinical
             assessment or put patient at risk.

          -  Active allergic contact dermatitis or other non-atopic forms of atopic dermatitis.

          -  Other concommitant serious illness or medical condition, virus or renal insufficiency,
             or clinically significant abnormality that could put patient at risk during the study.

          -  History of neurological/psychiatric disorders including psychotic disorders, dementia
             or any other reason that would interfere with the patient's participation.

          -  Systemic immunomodulatory therapies for other conditions within 4 weeks prior to the
             baseline visit.

          -  Any phototherapy, photochemotherapy or systemic atopic dermatitis therapy within 2
             weeks of the baseline visit.

          -  Prolonged exposure to natural or artificial sources of UV within 4 weeks prior to
             baseline visit or intention to have such exposure during the study.

          -  Topical atopic dermatitis therapies (including corticosteroids and calcineurins) in
             the areas to be treated within 2 weeks prior to baseline.

          -  Alcohol abuse in the last 2 years.

          -  Allergic history to any of the non-medical ingredients of the study cream.

          -  Treatment with an investigational drug within one month of Day 0 or current
             participation in another clinical trial.
Clinical trial NCT00054613 (phase 2, status: completed)
Conditions: graft-versus-host disease
ICD codes: D89.810, D89.811, D89.813, D89.812
Drugs: methoxsalen
SMILES: COC1=C2OC(=O)C=CC2=CC2=C1OC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Documented skin disease classical for chronic GvHD (e.g. hypopigmentation,
             hyperpigmentation, lichenoid lesions, sclerodermatous lesions)greater than or equal to
             100 days post transplantation.

          -  Patients with documented chronic GvHD that is corticosteroid refractory,
             corticosteroid dependent or corticosteroid intolerant.

          -  Women of childbearing potential must agree to use a reliable method of birth control
             for the duration of this study.

          -  Patients must weight at least 40 kg (88 lbs.)

        Exclusion Criteria:

          -  Active gastrointestinal bleeding

          -  Previous treatment with ECP

          -  Females who are pregnant and/or lactating
Clinical trial NCT00373516 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: vehicle (placebo) applied bid, qrx-101 75 mcg/g ointment applied qd, qrx-101 75 mcg/g ointment applied bid
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of stable plaque-type psoriasis affecting 2% to 10% of the
             subject's body surface area

          -  Psoriasis of a severity that is appropriate for treatment with topical therapy; PGA of
             at least 3 (moderate) at baseline; PSS of at least 7, and with no individual symptom
             score (erythema, induration, or scaling) less than 2

          -  Subject must sign the IRB approved informed consent and agree to follow dosing
             instructions and complete required clinic visits.

        Exclusion Criteria:

          -  Pregnant or nursing females

          -  Systemic corticosteroids, methotrexate, cyclosporine, systemic retinoids, prolonged
             sun exposure or ultraviolet light therapy within 4 weeks of dosing

          -  Topical corticosteroids, retinoids, calcipotriene, coal tar, anthralin, or any other
             treatment indicated for psoriasis within 2 weeks of dosing

          -  Untreated bacterial, tubercular, fungal or any viral lesion of the skin

          -  Biologic agents/monoclonal antibodies in the last 6 months

          -  Currently using lithium or plaquenil

          -  Currently using a beta-blocking medication or thiazide diuretic and the dose has not
             been stabilized for at least 6 months

          -  History of hypercalcemia or evidence of vitamin D toxicity

          -  Current or history of melanoma skin cancer in the past 5 years
Clinical trial NCT00400205 (phase 2, status: terminated)
Conditions: squamous cell carcinoma, oral cancer
ICD codes: C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42
Drugs: docetaxel, cisplatin, 5-fluorouracil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, FC1=CNC(=O)NC1=O
Reason stopped: 
    safety reasons
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven squamous cell carcinoma of the oral cavity.

          -  Primary tumor sites eligible: oral cavity. Although they are admittedly of squamous
             cell types, the following tumors will be excluded because their responsiveness to
             chemotherapy may differ: tumors of the nasal and paranasal cavities and of the
             nasopharynx. Oral cavity tumors with mandible invasion are excluded because the tumor
             biology and management of these tumors is more complex and will likely include upfront
             surgical resection.

          -  Stage 3 or 4 disease without evidence of distant metastases verified by chest x-ray,
             abdominal ultrasound, or CT scan (liver function test abnormalities); bone scan in
             case of local symptoms.

          -  At least one uni- or bi-dimensionally measurable lesion.

          -  Age ≥ 18 years.

          -  World Health Organization (WHO) performance status of 2 or less.

          -  No active alcohol addiction.

          -  Final eligibility for a clinical trial is determined by the health professionals
             conducting the trial.

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  Previous malignancies at other sites, with the exception of adequately treated in situ
             carcinoma of the cervix uteri, basal, or squamous cell carcinoma of the skin or other
             cancer curatively treated by surgery and with no evidence of disease for at least 5
             years.

          -  Any prior treatment with radiotherapy or chemotherapy is an exclusion criterion.

          -  Patients who experience an involuntary weight loss of more than 25% of their body
             weight in the 2 months preceding study entry.

          -  Concurrent treatment with any other anti-cancer therapy.

          -  Participation in an investigational trial within 30 days of study entry.

          -  Patients with a history of severe hypersensitivity reaction to Taxotere® or other
             drugs formulated with polysorbate 80.

          -  No previous chemotherapy or radiotherapy for any reason and no previous surgery for
             SCCHN [squamous cell carcinoma of the head and neck] (other than biopsy) are allowed
             at the time of study entry.

          -  Final eligibility for a clinical trial is determined by the health professionals
             conducting the trial.